Icahn School of Medicine at Mount Sinai · PharmacologyShi Nanobody Lab
Yi Shi · New York, New York
Research Focus
Dr. Yi Shi's lab focuses on developing innovative therapies to combat COVID-19 using unique nanobody technologies. The lab aims to create ultrapotent drug candidate cocktails that can neutralize various strains of the SARS-CoV-2 virus. By utilizing advanced proteomics and engineering techniques, the lab is working toward designing cost-effective and effective treatments that can be easily administered, even through inhalation.
nanobodiesSARS-CoV-2COVID-19 therapeuticsdrug developmentproteomicsviral neutralizationinhalation therapymultivalent constructsviral variantsepitope mapping
Research Aims
5AIM 01Identify and characterize potent nanobodies against SARS-CoV-2.
AIM 02Develop multivalent nanobody constructs resistant to virus variants.
AIM 03Investigate neutralization mechanisms using structural approaches.
AIM 04Create efficient therapeutic candidates ready for clinical trials.
AIM 05Establish a platform for rapid development of therapeutics for future pandemics.
Skills the Lab Values
nanobody engineeringproteomicsaerosol delivery systemsstructural biologyaffinity assaysin vitro infection modelsviral load analysisbioinformaticshigh-throughput screeningclinical trial design
Output against the department
Publications1,106top 2% of dept.8th of 462
this lab
most publishedleast published
Citations39ktop 6% of dept.28th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.